180 related articles for article (PubMed ID: 36708507)
1. EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines.
Nowaczyk J; Fret K; Kaminska-Winciorek G; Rudnicka L; Czuwara J
Anticancer Drugs; 2023 Sep; 34(8):942-948. PubMed ID: 36708507
[TBL] [Abstract][Full Text] [Related]
2. Successful Treatment with Fusidic Acid in a Patient with Folliculitis Decalvans.
Pimenta R; Borges-Costa J
Acta Dermatovenerol Croat; 2019 Mar; 27(1):49-50. PubMed ID: 31032795
[TBL] [Abstract][Full Text] [Related]
3. [Erlotinib-induced scarring alopecia with a folliculitis decalvans-like presentation].
Dervout C; Chiappa AM; Fleuret C; Plantin P; Acquitter M
Ann Dermatol Venereol; 2020 Dec; 147(12):848-852. PubMed ID: 33097309
[TBL] [Abstract][Full Text] [Related]
4. Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung Cancer.
Gisondi P; Geat D; Mattiucci A; Lombardo F; Santo A; Girolomoni G
Dermatology; 2021; 237(6):929-933. PubMed ID: 33508823
[TBL] [Abstract][Full Text] [Related]
5. Folliculitis decalvans associated with erlotinib.
Hoekzema R; Drillenburg P
Clin Exp Dermatol; 2010 Dec; 35(8):916-8. PubMed ID: 20456379
[No Abstract] [Full Text] [Related]
6. [Dapsone treatment of folliculitis decalvans].
Paquet P; Piérard GE
Ann Dermatol Venereol; 2004 Feb; 131(2):195-7. PubMed ID: 15026749
[TBL] [Abstract][Full Text] [Related]
7. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
8. EGFR inhibitor-associated acneiform folliculitis: assessment and management.
Duvic M
Am J Clin Dermatol; 2008; 9(5):285-94. PubMed ID: 18717603
[TBL] [Abstract][Full Text] [Related]
9. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
10. [Pityriasis amiantacea and folliculitis decalvans : An unusual manifestation associated with antitumor necrosis factor-α therapy].
Zamperetti M; Zelger B; Höpfl R
Hautarzt; 2017 Dec; 68(12):1007-1010. PubMed ID: 29038892
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.
Zhao Q; Shentu J; Xu N; Zhou J; Yang G; Yao Y; Tan F; Liu D; Wang Y; Zhou J
Lung Cancer; 2011 Aug; 73(2):195-202. PubMed ID: 21144613
[TBL] [Abstract][Full Text] [Related]
12. A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs.
Park JS; Hong MH; Chun YJ; Kim HR; Cho BC
Lung Cancer; 2019 Aug; 134():46-51. PubMed ID: 31319994
[TBL] [Abstract][Full Text] [Related]
13. Resolution of folliculitis decalvans with medical honey.
Yeh JE; Hartman RI; Xu J; Hoang M; Yasuda MR
Dermatol Online J; 2019 Aug; 25(8):. PubMed ID: 31553869
[TBL] [Abstract][Full Text] [Related]
14. Folliculitis decalvans--response to rifampin.
Brozena SJ; Cohen LE; Fenske NA
Cutis; 1988 Dec; 42(6):512-5. PubMed ID: 3229140
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of refractory folliculitis decalvans with secukinumab.
Ismail FF; Sinclair R
Australas J Dermatol; 2020 May; 61(2):165-166. PubMed ID: 31646619
[No Abstract] [Full Text] [Related]
16. Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.
Bachet JB; Peuvrel L; Bachmeyer C; Reguiai Z; Gourraud PA; Bouché O; Ychou M; Bensadoun RJ; Dreno B; André T
Oncologist; 2012; 17(4):555-68. PubMed ID: 22426526
[TBL] [Abstract][Full Text] [Related]
17. Folliculitis decalvans: Effectiveness of therapies and prognostic factors in a multicenter series of 60 patients with long-term follow-up.
Miguel-Gómez L; Rodrigues-Barata AR; Molina-Ruiz A; Martorell-Calatayud A; Fernández-Crehuet P; Grimalt R; Barco D; Arias-Santiago S; Serrano-Falcón C; Camacho FM; Saceda-Corralo D; Jaén-Olasolo P; Vañó-Galván S
J Am Acad Dermatol; 2018 Nov; 79(5):878-883. PubMed ID: 29864465
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Tumour Necrosis Factor-α Antagonists for Folliculitis Decalvans: A Retrospective Case-series Pilot Study.
Dupont A; Eyraud A; Milpied B; De Bataille S; Cassassa E; Darrigade AS; Barnetche T; Doutre MS; Matard B; Beylot-Barry M; Seneschal J
Acta Derm Venereol; 2023 Mar; 103():adv3713. PubMed ID: 36987539
[TBL] [Abstract][Full Text] [Related]
19. Photodynamic therapy for the treatment of folliculitis decalvans.
Castaño-Suárez E; Romero-Maté A; Arias-Palomo D; Borbujo J
Photodermatol Photoimmunol Photomed; 2012 Apr; 28(2):102-4. PubMed ID: 22409714
[TBL] [Abstract][Full Text] [Related]
20. Tufted folliculitis of the scalp: a distinctive clinicohistological variant of folliculitis decalvans.
Annessi G
Br J Dermatol; 1998 May; 138(5):799-805. PubMed ID: 9666825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
